AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05756478 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Medication review
Description: This is a feasibility study of implementing a pharmacist-led medication review using prescribing tools (e.g. STOPP/START, Beers Criteria)
Study NCT04432636 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Data collection of environmental factors
Description: - Data collection of environmental factors (including maternal nutrition and social level, mode of delivery, birth weight, mode of infant feeding, antibiotic treatments) at the recruitment
Study NCT04432636 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Collection of maternal feces
Description: - Collection of maternal feces: the first sample after delivery and once a week during the period of hospitalization of their infant (i.e. 5 to 8 samples per mother)
Study NCT04432636 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Collection of infant feces
Description: - Collection of infant feces: the first sample after birth and once a week during the period of hospitalization of the baby (i.e. 5 to 8 samples per mother) and a sample collected at the corrected age of 1 year and 2 years (i.e. 8 to 10 samples per infant)
Study NCT04432636 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: food questionnaire
Description: - A food questionnaire completed by the mother the week after delivery,
Study NCT04432636 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: a food questionnaire on the infant alimentation and food behavior during the period of 2 and 10 months of age
Description: a food questionnaire on the infant alimentation and food behavior during the period of 2 and 10 months of age, completed by the parents and given to the pediatrician at the medical check-up at the corrected age of 1 year
Study NCT04432636 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: a food questionnaire on the infant alimentation and food behavior during the period of 12 and 24 months of age
Description: a food questionnaire on the infant alimentation and food behavior during the period of 12 and 24 months of age, completed by the parents and given to the pediatrician at the medical check-up at the corrected age of 2 years
Study NCT04432636 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sample of milk
Description: A sample of 15 mL of milk drunk by the preterm at the 7th postnatal day (if not possible between the 7th and the 10th postnatal days).
Study NCT04432636 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: The 'Ages and Stages Questionnaire' ASQ
Description: - The 'Ages and Stages Questionnaire' ASQ survey completed by the parents and given to the pediatrician at the corrected age of 2 years medical check-up
Study NCT05054946 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cystectomy
Description: All surgeries will be performed under general anesthesia by laparoscopically.
Study NCT06374641 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mitochondrial Substrate Supplement
Description: Mitochondrial Substrate supplement, 2xdaily 65 mL drink
Study NCT05314257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granisetron Hydrochloride
Description: IV granisetron 1mg
Study NCT05314257 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% normal saline
Description: IV 5ml of 0.9% normal saline
Study NCT06374641 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Mitochondrial Substrate Supplement
Description: Mitochondrial Substrate supplement, 2xdaily 65 mL drink
Study NCT04584554 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BETTER Transitional Care Intervention
Description: Patient and family will receive pre- and post-discharge support and education from interventionist.
Study NCT06374641 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo Supplement
Description: Placebo supplement, 2xdaily 65 mL drink
Study NCT06374641 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Supplement
Description: Placebo supplement, 2xdaily 65 mL drink
Study NCT05450653 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FETO with Goldballoon Detachable Balloon (GOLDBAL2) along with the delivery Microcatheter (BALTACCI-BDPE100)
Description: A Goldballoon Detachable Balloon (GOLDBAL2) will be inserted in the airway of the fetus with severe congenital diaphragmatic hernia (o/e LHR \<25% with liver up) during the FETO procedure between gestational age 27 weeks 0 days and 29 weeks and 6 days. The fetal tracheal balloon will be removed at between 34 weeks 0 days and 34 weeks 6 days gestation or earlier as indicated.
Study NCT05581329 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture is a method of inserting very thin needles into special points on the body which are called acupoints. To conduct this intervention, we will use disposable acupuncture needles the size of 0.30 x 13 mm to acupuncture the control acupoint (Yuji - LU10) in the first session and the research acupoint (Houxi - SI3) in the second session.
Study NCT06093984 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: duostim vs. two antagonist ovarian stimulations
Description: Human menopausal gonadotropin (HMG) 300 IU/day with flexible antagonist protocol is used for ovarian stimulation, except in luteal phase stimulation of the duostim group. In the duostim group, all of the embryos are frozen. Fresh transfers are performed in the control group, frozen embryo transfers are performed in both control and duostim groups.
Study NCT06093984 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: duostim vs. two antagonist ovarian stimulations
Description: Human menopausal gonadotropin (HMG) 300 IU/day with flexible antagonist protocol is used for ovarian stimulation, except in luteal phase stimulation of the duostim group. In the duostim group, all of the embryos are frozen. Fresh transfers are performed in the control group, frozen embryo transfers are performed in both control and duostim groups.
Study NCT06287229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Given by Infusion
Study NCT06287229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin
Description: Given by IV
Study NCT06287229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyper-CVAD
Description: Given by IV Participants younger than 60 years of age, you will receive hyper-CVAD.
Study NCT06287229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mini-hyper-CVD
Description: Given by IV Participants 60 years of age or older, you will receive mini-hyper-CVD
Study NCT06144801 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoolSense Group
Description: Patients in the CoolSense group received a CoolSense device that had been pre-chilled in the freezer for a minimum of one hour. The cover of the CoolSense device was removed, and the arteriovenous fistula, whose metal tip had been cleaned with batikon, was brought into contact with the area where the arteriovenous fistula cannulation would occur. This contact was maintained for 5 seconds, involving circular movements, and the fistula cannulation took place promptly.
Study NCT04936880 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental : Virtual reality + analgesia-sedation
Description: Use of a virtual reality device + analgesia-sedation drugs according to SFMU/SFAR 2010 guidelines during reduction procedure
Study NCT04936880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control: Analgesia-sedation
Description: Use of analgesia-sedation drugs according to SFMU/SFAR 2010 guidelines during reduction procedure
Study NCT04893850 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BRIDGE Therapy Program
Description: The BRIDGE Therapy Program is a novel manualized therapy that incorporates key parenting concepts and related Dialectical Behavior Therapy (DBT) modules. The primary aim of the program is to improve parent well-being and promote supportive parenting practices. There are two components of the program: 1) the DBT section, which will follow the DBT Skills Training Manual 2nd Edition and target parental mental health symptomology, and 2) the parent skill training materials, which have been designed to correspond to the four core DBT modules (i.e., Mindfulness, Emotion Regulation, Distress Tolerance, and Interpersonal Effectiveness) and to promote self-regulatory skill development and a positive parent-child relationship.
Study NCT04893850 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Services as Usual Clinical Referral list
Description: The community services as usual clinical referral list provides information on accessing psychological and family support services in Winnipeg. This resource is used to locate: crisis, distress, and support phone lines, counselling and peer-support resources, and free apps relating to mindfulness and meditation.
Study NCT05689827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethyl methyl hydroxypyridine succinate + Meldonium
Description: Ethyl methyl hydroxypyridine succinate 100.0 mg/mL, meldonium dihydrate - 100.0 mg/mL (Solution for intravenous and intramuscular administration), then Ethyl methyl hydroxypyridine succinate - 250.0 mg, meldonium dihydrate based on dihydrate without adsorption moisture - 250.0 mg (oral capsules)
Study NCT05689827 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was used in the same way
Study NCT05045053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiidra 5% Ophthalmic Solution
Description: lifitegrast 0.5% ia applied twice daily after corneal collagen cross linking
Study NCT06073314 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative MRI
Description: Patients will be asked to remain in the scanner for an additional 10 minutes while we acquire additional quantitative MR images
Study NCT06414200 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: multidisciplinary structured tailored made nutritional advice
Description: The goal is a structured follow-up after discharge. Parents need to fill in questionnaires about eating behavior en feeding difficulties about their child. They also need to fill in a questionnaire about their stress. Together with their nutritional intake (3-days food diary) and growth a tailor-made nutritional plan is made. All the information I showed in a dashboard and discussed it with their dietitian. Who discusses this information in a multi-disciplinary team (pediatrician, psychologist and if needed a speech therapist).
Study NCT06122805 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toothbrush
Description: We will test three toothbrushes in patients undergoing surgery and a control no surgery group. These toothbrushes are manual toothbrushes, sonic toothbrushes, and sonic and dual light toothbrushes.
Study NCT05466942 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Pulse Oximeter, Respiratory Rate, Heart Rate
Description: Measurement of physiological parameters
Study NCT06646055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112, Cadonilimab, nab-paclitaxel, gemcitabine
Description: IV infusion, specified dose on specified days.
Study NCT06644300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BM230
Description: SC injection
Study NCT06073314 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Reproducibility study
Description: A subset of patients will be invited back for a repeat MRI scan (prior to any treatment for their condition) to help measure reproducibility of our Artificial Intelligence model
Study NCT04799665 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Breast CT
Description: This is a cross-sectional clinical study to determine the feasibility of breast CT for breast density assessment and association of CT-derived density measures with metabolic syndrome in overweight/obese Mexican-origin women in Southern Arizona. There is no intervention.
Study NCT04673903 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Copenhagen adduction exercise
Description: The Copenhagen Adduction exercise is a simple isolated eccentric partner exercise and doesn't require special equipment and can be performed as a warm up activity on the pitch.
Study NCT06646055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112, nab-paclitaxel, gemcitabine
Description: IV infusion, specified dose on specified days.
Study NCT06646055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-paclitaxel, gemcitabine
Description: IV infusion, specified dose on specified days.
Study NCT04673903 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual warm up
Description: Usual warm up is defined as any basic exercises performed before a performance or practice to prepare the muscles for vigorous actions.
Study NCT06163781 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood culture prediction tool
Description: Machine learning based predicition tool
Study NCT06296693 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pocket-size lung ultrasound for etiological definition of pneumonia and surveillance of complications in children hospitalized
Description: The investigators will study the diagnostic accuracy of a pocket-size POCUS device vs. CXR for the etiological diagnosis of CAP, in paediatric age. During 1 year, all children aged >12 months and \<18 years admitted to the Paediatric Department with the diagnosis of CAP on admission will be included. At least 76 participants will be required. Two investigators will perform, independently, a POCUS at admission, daily during hospitalization, 15 days and 1 month after discharge. All children will also undergo a CXR upon admission and whenever necessary. A third investigator will classify the CXR independently. It will be used the General Electrics Vscan AirTM®, with Bluetooth connection to smartphone/tablet. It will be collected the systematized description of POCUS and CXR, sociodemographic, clinical and therapeutic variables.
Study NCT05932680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Off Drug Surveillance
Description: After stopping teclistamab, participants will be monitored monthly by standard serum paraprotein studies for disease progression. Participants will resume teclistamab at time of disease progression. After Teclistamab therapy re-initiation on-study, monthly response assessments and data for other study endpoints will be obtained. All participants will undergo peripheral blood collection for correlative research studies at baseline and every two months on-study. Participants who enroll on the biomarker sub-study will undergo bone marrow examination and peripheral blood collection for correlative studies at study entry, at time of disease progression and at six months from enrollment.
Study NCT06153212 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Membrane placement with bone grafting
Description: The diseased dental implant will be cleaned and the bone defect will be filled with bone graft and covered by a membrane.
Study NCT06153212 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Membrane placement with bone grafting
Description: The diseased dental implant will be cleaned and the bone defect will be filled with bone graft and covered by a membrane.
Study NCT05408065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Hexacetonide and hyaluronic acid
Description: infiltration under fluoroscopy
Study NCT05408065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Hexacetonide
Description: infiltration under fluoroscopy
Study NCT05638984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine Injection
Description: Injection site citabine, 10 mg/ bottle, 10 mg/d, Q3W, D1-D5 intravenous infusion; Tirelizumab injection 200mg D5 intravenous infusion
Study NCT05638984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tirelizumab
Description: 10ml: 100mg / 1 bottle, 200mg, Q3W, D1 i. v. infusion.
Study NCT05638984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tirelizumab
Description: 10ml: 100mg / 1 bottle, 200mg, Q3W, D1 i. v. infusion.
Study NCT06016660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Resistance exercise, Neuromuscular electrical stimulation, and Transcutaneous electrical stimulation
Study NCT05750667 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cascade screening
Description: FH is a genetic condition that causes high LDL cholesterol starting at birth. When one individual with FH is diagnosed, it is important that biological family members are also screened, since there is a 50% chance that each first-degree relative will have also inherited FH. More distant relatives may also have inherited FH. This evidence-based process is known as cascade screening.
Study NCT05965570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brensocatib
Description: Oral tablets.
Study NCT05965570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Oral tablets.
Study NCT06465901 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine Gluconate 2.0% to 4.0% (e.g. Hibiscrub) preoperative shower
Description: Chlorhexidine Gluconate 2.0% to 4.0% (e.g. Hibiscrub) preoperative shower
Study NCT06465901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Gluconate 2.0% to 4.0% (e.g. Hibiscrub) preoperative shower
Description: Chlorhexidine Gluconate 2.0% to 4.0% (e.g. Hibiscrub) preoperative shower
Study NCT06465901 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative wound wash (e.g. Granudacyn)
Description: Intraoperative wound wash (e.g. Granudacyn)
Study NCT06465901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraoperative wound wash (e.g. Granudacyn)
Description: Intraoperative wound wash (e.g. Granudacyn)
Study NCT06465901 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DACC surgical wound dressing (e.g. Leukomed Sorbact)
Description: DACC surgical wound dressing (e.g. Leukomed Sorbact)
Study NCT06465901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DACC surgical wound dressing (e.g. Leukomed Sorbact)
Description: DACC surgical wound dressing (e.g. Leukomed Sorbact)
Study NCT05697692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin sodium
Description: Lung transplantation on central veno-arterial ECMO with standard additional heparin
Study NCT05697692 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lung transplantation on central veno-arterial ECMO without additional heparin
Study NCT06470464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide combined with TGA chemotherapy (nab-paclitaxel + gemcitabine+ epirubicin)
Description: The oral dose of thalidomide is 1.5-2.5mg/kg/d daily (maximum 28g). Each cycle lasts for 21 days (every three weeks), and if treatment parameters are met as described in the study, cycle two and subsequent cycles begin on day 22. Treatment will be discontinued if there is drug-related dose-limiting toxicity or disease progression. Tumor response assessment will be repeated using AFP and LDH every one cycle and imaging examination every two cycles. Children who complete the trial may continue this regimen or undergo surgery or radiation therapy if their disease goes into remission.
Study NCT06257121 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OSMS position management
Description: Patient position management in real time during radiation using an optical Surface Management System (OSMS) (Vision RT)
Study NCT05770076 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic lysate (postbiotic and metabiotic)
Description: Each capsule contains 100 mg of cell lysate and DNA fragments of the probiotic strain L. rhamnosus DV - NRRLB-68023 in powder
Study NCT05770076 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04858126 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECOM cardiac output
Description: Measure cardiac output during perioperative period and compare to pulmonary artery catheter thermal dilution cardiac output measurement.
Study NCT06046053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Vaginal Film with Square Corners
Description: 2 x 2 placebo vaginal film with square corners
Study NCT06046053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Vaginal Film with Rounded Corners
Description: 2 x 2 placebo vaginal film with rounded corners
Study NCT04317846 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous administration of vasodilatory drugs
Description: Administration of the vasodilatory drugs in a different pattern than intra-arterially
Study NCT04317846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous administration of vasodilatory drugs
Description: Administration of the vasodilatory drugs in a different pattern than intra-arterially
Study NCT05644418 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flow Controlled Ventilation (FCV)
Description: FCV is started with the same settings as PCV (PEEP, Ppeak, FiO2) and after 30 minutes FCV is optimized concerning the driving pressure and PEEP using the dynamic compliance. After a total of 60 minutes the flow is adjusted based on the arterial blood gas.
Study NCT05419258 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UPLUG Hemodialysis Connection Device
Description: use of the device UPLUG during 1 month
Study NCT05418946 — intervention group
Intervention type: DRUG
Intervention: Dapagliflozin 10mg
Description: Treatment of T2D and cardio-renal prevention